# A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects

> **NCT00537420** · PHASE2 · COMPLETED · sponsor: **Nastech Pharmaceutical Company, Inc.** · enrollment: 551 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Nasal Placebo
- **DRUG:** Placebo Capsule
- **DRUG:** PYY3-36
- **DRUG:** PYY3-36
- **DRUG:** PYY3-36
- **DRUG:** Sibutramine

## Key facts

- **NCT ID:** NCT00537420
- **Lead sponsor:** Nastech Pharmaceutical Company, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-07
- **Final completion:** 2008-09
- **Target enrollment:** 551 (ACTUAL)
- **Last updated:** 2008-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00537420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00537420, "A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00537420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*